Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy

Carolina Ciacci,1 Mario Gagliardi,1 Monica Siniscalchi,1 Monica Ruotolo,1 Antonella Santonicola,1 Najla Hajji,1 Fabiana Zingone2 1Celiac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy; 2Gastroenterology Unit, Department of S...

Full description

Bibliographic Details
Main Authors: Ciacci C, Gagliardi M, Siniscalchi M, Ruotolo M, Santonicola A, Hajji N, Zingone F
Format: Article
Language:English
Published: Dove Medical Press 2021-11-01
Series:Clinical and Experimental Gastroenterology
Subjects:
Online Access:https://www.dovepress.com/gluten-immunogenic-peptides-gip-point-of-care-urine-test-in-coeliac-di-peer-reviewed-fulltext-article-CEG
_version_ 1819041380948770816
author Ciacci C
Gagliardi M
Siniscalchi M
Ruotolo M
Santonicola A
Hajji N
Zingone F
author_facet Ciacci C
Gagliardi M
Siniscalchi M
Ruotolo M
Santonicola A
Hajji N
Zingone F
author_sort Ciacci C
collection DOAJ
description Carolina Ciacci,1 Mario Gagliardi,1 Monica Siniscalchi,1 Monica Ruotolo,1 Antonella Santonicola,1 Najla Hajji,1 Fabiana Zingone2 1Celiac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy; 2Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, ItalyCorrespondence: Carolina CiacciCeliac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, Salerno, 84081, ItalyEmail cciacci@unisa.itIntroduction: Celiac disease (CeD) diagnosis has worldwide shared protocols. Conversely, follow-up of patients is still an object of study. Gluten immunogenic peptide detection in the urine (GIP) appears to be a new and efficient method for dietary gluten control of patients. The present study aims to assess the clinical usefulness of the GIP point-of-care urine test in the follow-up of symptomatic and asymptomatic patients with CeD before and during the COVID-19 lockdown in Italy.Methods: Thirty adult CeD patients on a gluten-free diet (GFD) were enrolled before and during the COVID-19 lockdown through follow-up visits or remote consultation. Patients underwent anthropometrical evaluation, dietetic interview, and State-Trait Anxiety Inventory (STAI). Then, two groups were formed: symptomatic and worried about gluten contamination. Each patient received 5 GIP point-of-care tests to perform a maximum of 5 times in the following 5 weeks in case of symptoms or anxiety state due to hypothesized gluten contamination.Results: Sixteen symptomatic patients and 14 patients with concerns related to gluten contamination were included. There were no differences in age, BMI, compliance to GFD and GIP positive tests between the two groups. Worried group showed a borderline higher level of anxiety than symptomatic group (p = 0.06), with a significant minor percentage of patients reporting “no or low anxiety” (14.3% vs 50% p = 0.03). The symptomatic patients showed a higher rate of diarrhea than worried group (25% vs 0%, p = 0.04). Gluten in urine samples was globally found in 8 out of 30 cases (26.6%).Conclusion: The GIP test is a tool that can be used as a point of care test to assess adequate compliance with GFD and reassure symptomatic CeD patients from the feeling of anxiety for gluten contamination, especially during the COVID-19 pandemic.Keywords: GIP, POCT gluten contamination, GFD, anxiety, burden, celiac disease
first_indexed 2024-12-21T09:24:05Z
format Article
id doaj.art-1c216ffca0044d71bcdbd9a51dee9c7c
institution Directory Open Access Journal
issn 1178-7023
language English
last_indexed 2024-12-21T09:24:05Z
publishDate 2021-11-01
publisher Dove Medical Press
record_format Article
series Clinical and Experimental Gastroenterology
spelling doaj.art-1c216ffca0044d71bcdbd9a51dee9c7c2022-12-21T19:08:57ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232021-11-01Volume 1445145670657Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in ItalyCiacci CGagliardi MSiniscalchi MRuotolo MSantonicola AHajji NZingone FCarolina Ciacci,1 Mario Gagliardi,1 Monica Siniscalchi,1 Monica Ruotolo,1 Antonella Santonicola,1 Najla Hajji,1 Fabiana Zingone2 1Celiac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy; 2Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, ItalyCorrespondence: Carolina CiacciCeliac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, Salerno, 84081, ItalyEmail cciacci@unisa.itIntroduction: Celiac disease (CeD) diagnosis has worldwide shared protocols. Conversely, follow-up of patients is still an object of study. Gluten immunogenic peptide detection in the urine (GIP) appears to be a new and efficient method for dietary gluten control of patients. The present study aims to assess the clinical usefulness of the GIP point-of-care urine test in the follow-up of symptomatic and asymptomatic patients with CeD before and during the COVID-19 lockdown in Italy.Methods: Thirty adult CeD patients on a gluten-free diet (GFD) were enrolled before and during the COVID-19 lockdown through follow-up visits or remote consultation. Patients underwent anthropometrical evaluation, dietetic interview, and State-Trait Anxiety Inventory (STAI). Then, two groups were formed: symptomatic and worried about gluten contamination. Each patient received 5 GIP point-of-care tests to perform a maximum of 5 times in the following 5 weeks in case of symptoms or anxiety state due to hypothesized gluten contamination.Results: Sixteen symptomatic patients and 14 patients with concerns related to gluten contamination were included. There were no differences in age, BMI, compliance to GFD and GIP positive tests between the two groups. Worried group showed a borderline higher level of anxiety than symptomatic group (p = 0.06), with a significant minor percentage of patients reporting “no or low anxiety” (14.3% vs 50% p = 0.03). The symptomatic patients showed a higher rate of diarrhea than worried group (25% vs 0%, p = 0.04). Gluten in urine samples was globally found in 8 out of 30 cases (26.6%).Conclusion: The GIP test is a tool that can be used as a point of care test to assess adequate compliance with GFD and reassure symptomatic CeD patients from the feeling of anxiety for gluten contamination, especially during the COVID-19 pandemic.Keywords: GIP, POCT gluten contamination, GFD, anxiety, burden, celiac diseasehttps://www.dovepress.com/gluten-immunogenic-peptides-gip-point-of-care-urine-test-in-coeliac-di-peer-reviewed-fulltext-article-CEGgippoct gluten contaminationgfdanxietyburdenceliac disease
spellingShingle Ciacci C
Gagliardi M
Siniscalchi M
Ruotolo M
Santonicola A
Hajji N
Zingone F
Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
Clinical and Experimental Gastroenterology
gip
poct gluten contamination
gfd
anxiety
burden
celiac disease
title Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
title_full Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
title_fullStr Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
title_full_unstemmed Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
title_short Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
title_sort gluten immunogenic peptides gip point of care urine test in coeliac disease follow up before and during the covid 19 lockdown in italy
topic gip
poct gluten contamination
gfd
anxiety
burden
celiac disease
url https://www.dovepress.com/gluten-immunogenic-peptides-gip-point-of-care-urine-test-in-coeliac-di-peer-reviewed-fulltext-article-CEG
work_keys_str_mv AT ciaccic glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT gagliardim glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT siniscalchim glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT ruotolom glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT santonicolaa glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT hajjin glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly
AT zingonef glutenimmunogenicpeptidesgippointofcareurinetestincoeliacdiseasefollowupbeforeandduringthecovid19lockdowninitaly